Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels.
The authors present an overview of the existing cost-effectiveness studies of ADT in prostate cancer. Cost-effectiveness of ADT was reviewed using a systematic search of the peer-reviewed literature, as well as research abstracts presented at various scientific and industry meetings. Most cost-effectiveness analyses of ADT reported results within the accepted societal threshold of US$50,000 cost/quality-adjusted life year needed to adopt new technology.
Written by:
Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. Are you the author?
Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA.
Reference: Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):251-9.
doi: 10.1586/erp.13.12
PubMed Abstract
PMID: 23570436
UroToday.com Prostate Cancer Section
